A New Antitrust Approach After Humira 'Patent Thicket' Ruling
The U.S. District Court for the Northern District of Illinois recently found in the Humira antitrust litigation that AbbVie Inc.'s so-called patent thicket surrounding its Humira product does not violate the...To view the full article, register now.
Already a subscriber? Click here to view full article